Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who want monthly injections instead of daily pills.
A study finds that long-acting cabotegravir is an effective PrEP option for women.
Cabotegravir injections and daily Truvada are both highly effective, but some people may find it easier to use the long-acting regimen.
Monthly islatravir pills are just one of the long-acting options in the HIV prevention pipeline.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.
The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.
The HIV advocacy group has been assiduously tracking PrEP data for five years.
We asked participants and presenters at the #AIDS2020Virtual what was compelling to them about the gathering. Here are their responses.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.